{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:34Z","timestamp":1785300154406,"version":"3.55.0"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"S 01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to structural differences between extended half-life (EHL) factor VIII (FVIII) or FIX products and equivalent plasma wild-type molecules used for assay calibration, reagent-dependent discrepancies during monitoring of FVIII- and FIX-replacement therapies with EHL products have been described. To assess the performance of available one-stage clotting and chromogenic substrate assays on the Siemens Atellica COAG 360 analyzer, an in vitro study using spiked plasma samples was performed. The described results confirm previously described findings and allowed allocation of each EHL product to an appropriate assay. In addition, corresponding EHL product\u2013specific analytes were defined within the order entry system of the University Hospital Bonn. The requirement of product-specific FVIII and FIX assays complicates patient monitoring and demonstrates the need for both continuous education and communication between treating physicians and the coagulation laboratory.<\/jats:p>","DOI":"10.1055\/a-1282-2251","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T23:38:50Z","timestamp":1605310730000},"page":"S15-S20","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["Extended Half-Life Factor VIII\/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management"],"prefix":"10.1055","volume":"40","author":[{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Goldmann","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Marquardt","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"P\u00f6tzsch","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"University Hospital Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"P H Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0034-1381232","article-title":"The history of hemophilia","volume":"40","author":"M Franchini","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"S 01","key":"ref3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.thromres.2013.10.020","article-title":"The history of haemophilia - a short review","volume":"134","author":"W Schramm","year":"2014","journal-title":"Thromb Res"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ijlh.12877","article-title":"Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B","volume":"40","author":"D M Adcock","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0037-1619052","article-title":"Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype","volume":"30","author":"J Oldenburg","year":"2010","journal-title":"Hamostaseologie"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH13-08-0690","article-title":"Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays","volume":"111","author":"A Pavlova","year":"2014","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00277-019-03691-1","article-title":"In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies","volume":"98","author":"B Pezeshkpoor","year":"2019","journal-title":"Ann Hematol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1365-2516.1998.440646.x","article-title":"Influence of phospholipids on the assessment of factor VIII activity","volume":"4","author":"M Mikaelsson","year":"1998","journal-title":"Haemophilia"},{"issue":"S 04","key":"ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(01)90104-0","article-title":"Measurement of factor VIII activity of B-domain deleted recombinant factor VIII","volume":"38","author":"M Mikaelsson","year":"2001","journal-title":"Semin Hematol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.12449","article-title":"Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays","volume":"20","author":"H V Wilmot","year":"2014","journal-title":"Haemophilia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.12.012","article-title":"Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges","author":"P Chowdary","year":"2019","journal-title":"Thromb Res"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays","volume":"18","author":"F Peyvandi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ijlh.13119","article-title":"Evaluation of the Atellica COAG 360 coagulation analyzer in a central laboratory of a maximum care hospital","volume":"42","author":"S H\u00f6rber","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-016-0622-z","article-title":"Efmoroctocog alfa: a review in haemophilia A","volume":"76","author":"J E Frampton","year":"2016","journal-title":"Drugs"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-019-01152-7","article-title":"Damoctocog alfa pegol: a review in haemophilia A","volume":"79","author":"J Paik","year":"2019","journal-title":"Drugs"},{"issue":"15","key":"ref16","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-017-0815-0","article-title":"Lonoctocog alfa: a review in haemophilia A","volume":"77","author":"Z T Al-Salama","year":"2017","journal-title":"Drugs"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"B A Konkle","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/hae.13897","article-title":"An overview of turoctocog alfa pegol (N8-GP; ESPEROCT\u00ae ) assay performance: Implications for postadministration monitoring","volume":"26","author":"M Ezban","year":"2020","journal-title":"Haemophilia"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40265-016-0679-8","article-title":"Coagulation factor IX (Recombinant), albumin fusion protein (albutrepenonacog alfa; Idelvion\u00ae): a review of its use in haemophilia B","volume":"77","author":"K A Lyseng-Williamson","year":"2017","journal-title":"Drugs"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-017-0778-1","article-title":"Eftrenonacog alfa: a review in haemophilia B","volume":"77","author":"S M Hoy","year":"2017","journal-title":"Drugs"},{"issue":"18","key":"ref21","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s40265-017-0836-8","article-title":"Nonacog beta pegol: a review in haemophilia B","volume":"77","author":"Y Y Syed","year":"2017","journal-title":"Drugs"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jth.14394","article-title":"Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice","volume":"17","author":"G A Young","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/hae.13907","article-title":"Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"E Gray","year":"2020","journal-title":"Haemophilia"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jth.13359","article-title":"Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX","volume":"14","author":"P Ros\u00e9n","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jth.13932","article-title":"International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories","volume":"16","author":"K St Ledger","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/hae.12634","article-title":"Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators","volume":"21","author":"J Dodt","year":"2015","journal-title":"Haemophilia"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"J M Sommer","year":"2014","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2019-125491","article-title":"Inter-laboratory evaluation of the recovery of Bay 94-9027 [Jivi\u00ae] with one-stage clotting and chromogenic assays","volume":"134","author":"P Meijer","year":"2019","journal-title":"Blood"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.13168","article-title":"Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study","volume":"23","author":"A Hillarp","year":"2017","journal-title":"Haemophilia"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hae.13001","article-title":"A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE","volume":"22","author":"P L Turecek","year":"2016","journal-title":"Haemophilia"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1111\/hae.13250","article-title":"Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study","volume":"23","author":"O Bulla","year":"2017","journal-title":"Haemophilia"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2010.04.004","article-title":"The \u201cnormal\u201d factor VIII concentration in plasma","volume":"126","author":"S Butenas","year":"2010","journal-title":"Thromb Res"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1282-2251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T23:39:28Z","timestamp":1605310768000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1282-2251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"journal-issue":{"issue":"S 01","published-online":{"date-parts":[[2020,11,13]]},"published-print":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1282-2251","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}